Pharmafile Logo

So, what is happening with specialised commissioning in the NHS?

Specialised commissioning continues to be an issue of significance and uncertainty for both the NHS and industry. What do the latest reports of regional push back on the plans for devolution to Integrated Care Boards (ICBs) mean? Join us for free live webinar.

What’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty?

Join Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) and David Thorne (Principal Associate, Mtech Access) for our live webinar on Friday 8th December at 2.00pm, as they explore specialised commissioning in the NHS and what to expect as we head into 2024. Webinar registration is now open here.

Specialised commissioning continues to be an issue of significance and uncertainty for both the NHS and industry. What do the latest reports of regional push back on the plans for devolution to Integrated Care Boards (ICBs) mean? Learn more about our upcoming webinar here.

For the past 2 years, Pharma, Medtech, and Diagnostic companies have identified the delegation of specialised commissioning to the new Integrated Care Boards (ICBs) as a key risk to their UK market access strategies. With its importance to income and the high risk of change devolution seems to promise, specialised commissioning is an obvious issue for providers of these products to place at the top of their risk logs.

The devolution plans are also a risk for the NHS. Not least, because around two-thirds of the income of a typical regional tertiary centre hospital’s income currently comes from specialised services. These are high-cost, low-volume services treating the most vulnerable and intensive patients.

Such services have always been managed on an insurance risk basis through regional consortia of commissioners and providers. For the past 10 years or so, we have seen NHS England (NHSE) centrally manage ‘spec comm’. Here, a central tenet has been that the high-cost medicines involved have been paid for as a pass-through cost with no local financial impact to hospitals or their local commissioners.

For 2 years we have seen complex and sporadic communication of NHSE’s plan to delegate spec comm and its funding to ICBs. This is intended to be a graduated process involving nine regionalised Joint Committees, bringing together NHSE and groups of ICBs. The plans are based on specialised services being grouped into three cohorts of services:

  • Those that will be delegated
  • Those that may be delegated
  • Those that will remain centrally-managed by NHSE

This plan has major risks, especially as it has an inherent paradox. All policy announcements commit to consistent application of NICE and CRG advice, but the delegated funding will undergo weighted capitation, and will therefore vary considerably. So how can services be provided on an equitable basis?

There are other risks too. There is little evidence of practical work to ensure that patient pathways, cross-boundary flows, inter-hospital agreements, and other issues have been addressed. Clinical engagement has been marginal at best. How then is the NHS ready to safely move to new ways of working from 1st April 2024 with the most expensive, complex, and clinically-sensitive services?

On 1st November 2023, the South Yorkshire ICB public board meeting threw arrangements into the air in three sentences:

“Discussions are continuing between NHS England and the ICBs in the North East and Yorkshire regarding the delegation of responsibility for commissioning Specialised Services from April 2024. It has now been agreed by all parties that the transfer of responsibility will be deferred until April 2025. This will allow for further due diligence to be undertaken and ensure a safe transfer of this responsibility.”

So far, others have not made such a public statement of delay. The North East and Yorkshire region is generally regarded as more stable and financially secure than others. It also has simpler cross-boundary flows than others (most notably those with patient flows into the London centres).

If this region sees risks that prompt a delay, and can secure NHSE agreement to that, then where does it leave the others? and, how can you have a major Region working to one set of rules and the others at variance?

This leaves Pharma, Medtech, and Diagnostics in a position that requires even greater urgent and accurate scenario-planning surrounding the possible impact upon all aspects of business. That’s before considering actions to mitigate risk and develop opportunities. The absolute basics of market access are unclear – who sets the rules, who decides, who pays?

There has rarely been a time when so much is so unclear regarding an area that is so important to business, the NHS, and to patients.

Our response and upcoming webinar

In our briefings to clients, we have consistently explained, highlighted, and anticipated this policy arena. Webinars and symposia have reinforced those messages.

On 8th December, our final NHS Whispers webinar of 2023 will explore this topic in more detail. Join David Thorne (Principal Associate, Mtech Access) in his interview of Malcolm Qualie (former Medicines Lead for Specialised Services within NHS England) for an exploration of the state of play and what to expect in 2024.

In this new NHS Whispers webinar, Malcolm Qualie and David Thorne will explore:

  • Specialised commissioning in the NHS
  • The risks and opportunities that devolution to ICBs will bring
  • What we can expect to see in the short and longer term
  • How industry can support ICB leaders through this transition
  • How Pharma, Medtech, and Diagnostics companies, whose products come under specialised commissioning, can manage these risks and uncertainties

Learn more and register now at: https://mtechaccess.co.uk/nhs-specialised-commissioning/

This content was provided by Mtech Access

Company Details

 Latest Content from  Mtech Access 

The role of economic evaluation in US healthcare

Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US. They highlight important considerations for companies seeking...

What role does ICER play in US market access?

The Institute for Clinical and Economic Review (ICER) is becoming an increasingly important player in US market access. As more transformative, but costly, treatments come to market, payers must continue...

Mtech Access are exhibiting at ISPOR in the US

After many years attending ISPOR Europe, Mtech Access are excited to be attending the Global ISPOR conference May 5-8. Mtech Access are inviting ISPOR delegates to come by stand 125...

Market access and reimbursement in Canada – changes at CADTH

What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health...

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as the Mtech Access experts give their hot take on each...

Rare disease market access – Launching orphan drugs in secondary markets: the Nordic and MENA regions

Join us live at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February, to explore rare disease market access challenges and learn more about these high potential markets.

The pitfalls of cutting costs on systematic literature reviews: 11 common issues to avoid

Embarking on a systematic literature review is a critical step in evidence synthesis, providing a foundation for robust decision-making in the healthcare landscape. As with most things, there are ways...

How does funding flow in NHSE Regions? – Live Webinar

On Friday 23rd February at 2.00pm, we will sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion...

Digital options to enhance your local market access materials

How can a digital approach enhance local customer communication, particularly when tools are adapted from existing global materials? What are the options? How can we build in efficiencies whilst meeting...

So, what is happening with specialised commissioning in the NHS?

Specialised commissioning continues to be an issue of significance and uncertainty for both the NHS and industry. What do the latest reports of regional push back on the plans for...